vs
Side-by-side financial comparison of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) and Shake Shack Inc. (SHAK). Click either name above to swap in a different company.
INTEGRA LIFESCIENCES HOLDINGS CORP is the larger business by last-quarter revenue ($434.9M vs $400.5M, roughly 1.1× Shake Shack Inc.). On growth, Shake Shack Inc. posted the faster year-over-year revenue change (21.9% vs -1.7%). Shake Shack Inc. produced more free cash flow last quarter ($4.0M vs $-5.4M). Over the past eight quarters, Shake Shack Inc.'s revenue compounded faster (17.4% CAGR vs 8.6%).
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
Shake Shack is an American multinational fast casual restaurant chain based in New York City. It started out as a hot dog cart inside Madison Square Park in 2001, and its popularity steadily grew. In 2004, it received a permit to open a permanent kiosk within the park, expanding its menu from New York–style hot dogs to one with hamburgers, hot dogs, fries and its namesake milkshakes.
IART vs SHAK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $434.9M | $400.5M |
| Net Profit | — | $11.8M |
| Gross Margin | 50.8% | — |
| Operating Margin | 5.3% | 4.7% |
| Net Margin | — | 3.0% |
| Revenue YoY | -1.7% | 21.9% |
| Net Profit YoY | — | 35.8% |
| EPS (diluted) | $-0.03 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $434.9M | $400.5M | ||
| Q3 25 | $402.1M | $367.4M | ||
| Q2 25 | $415.6M | $356.5M | ||
| Q1 25 | $382.7M | $320.9M | ||
| Q4 24 | $442.6M | $328.7M | ||
| Q3 24 | $380.8M | $316.9M | ||
| Q2 24 | $418.2M | $316.5M | ||
| Q1 24 | $368.9M | $290.5M |
| Q4 25 | — | $11.8M | ||
| Q3 25 | $-5.4M | $12.5M | ||
| Q2 25 | $-484.1M | $17.1M | ||
| Q1 25 | $-25.3M | $4.2M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | $-10.7M | $-10.2M | ||
| Q2 24 | $-12.4M | $9.7M | ||
| Q1 24 | $-3.3M | $2.0M |
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.5% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | 54.0% | — | ||
| Q1 24 | 56.1% | — |
| Q4 25 | 5.3% | 4.7% | ||
| Q3 25 | 2.9% | 5.0% | ||
| Q2 25 | -123.4% | 6.3% | ||
| Q1 25 | -4.0% | 0.9% | ||
| Q4 24 | 8.0% | 3.1% | ||
| Q3 24 | -2.1% | -5.7% | ||
| Q2 24 | -0.7% | 3.4% | ||
| Q1 24 | 1.1% | 0.0% |
| Q4 25 | — | 3.0% | ||
| Q3 25 | -1.3% | 3.4% | ||
| Q2 25 | -116.5% | 4.8% | ||
| Q1 25 | -6.6% | 1.3% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -2.8% | -3.2% | ||
| Q2 24 | -3.0% | 3.1% | ||
| Q1 24 | -0.9% | 0.7% |
| Q4 25 | $-0.03 | $0.28 | ||
| Q3 25 | $-0.07 | $0.30 | ||
| Q2 25 | $-6.31 | $0.41 | ||
| Q1 25 | $-0.33 | $0.10 | ||
| Q4 24 | $0.25 | $0.22 | ||
| Q3 24 | $-0.14 | $-0.26 | ||
| Q2 24 | $-0.16 | $0.23 | ||
| Q1 24 | $-0.04 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $263.7M | $360.1M |
| Total DebtLower is stronger | $726.6M | $247.7M |
| Stockholders' EquityBook value | $1.0B | $525.3M |
| Total Assets | $3.6B | $1.9B |
| Debt / EquityLower = less leverage | 0.70× | 0.47× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $263.7M | $360.1M | ||
| Q3 25 | $267.9M | $357.8M | ||
| Q2 25 | $253.6M | $336.8M | ||
| Q1 25 | $273.3M | $312.9M | ||
| Q4 24 | $273.6M | $320.7M | ||
| Q3 24 | $277.6M | $310.9M | ||
| Q2 24 | $296.9M | $304.4M | ||
| Q1 24 | $663.1M | $284.8M |
| Q4 25 | $726.6M | $247.7M | ||
| Q3 25 | $736.3M | $247.5M | ||
| Q2 25 | $745.9M | $247.2M | ||
| Q1 25 | $755.6M | $246.9M | ||
| Q4 24 | $760.5M | $246.7M | ||
| Q3 24 | $765.3M | $246.4M | ||
| Q2 24 | $770.2M | $246.2M | ||
| Q1 24 | $775.0M | $245.9M |
| Q4 25 | $1.0B | $525.3M | ||
| Q3 25 | $1.0B | $509.0M | ||
| Q2 25 | $1.0B | $494.1M | ||
| Q1 25 | $1.5B | $473.3M | ||
| Q4 24 | $1.5B | $470.0M | ||
| Q3 24 | $1.5B | $456.1M | ||
| Q2 24 | $1.5B | $462.4M | ||
| Q1 24 | $1.6B | $446.4M |
| Q4 25 | $3.6B | $1.9B | ||
| Q3 25 | $3.6B | $1.8B | ||
| Q2 25 | $3.7B | $1.8B | ||
| Q1 25 | $4.1B | $1.7B | ||
| Q4 24 | $4.0B | $1.7B | ||
| Q3 24 | $4.1B | $1.7B | ||
| Q2 24 | $4.1B | $1.7B | ||
| Q1 24 | $4.1B | $1.6B |
| Q4 25 | 0.70× | 0.47× | ||
| Q3 25 | 0.71× | 0.49× | ||
| Q2 25 | 0.72× | 0.50× | ||
| Q1 25 | 0.50× | 0.52× | ||
| Q4 24 | 0.49× | 0.52× | ||
| Q3 24 | 0.50× | 0.54× | ||
| Q2 24 | 0.50× | 0.53× | ||
| Q1 24 | 0.48× | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.8M | $63.1M |
| Free Cash FlowOCF − Capex | $-5.4M | $4.0M |
| FCF MarginFCF / Revenue | -1.2% | 1.0% |
| Capex IntensityCapex / Revenue | 4.0% | 14.8% |
| Cash ConversionOCF / Net Profit | — | 5.34× |
| TTM Free Cash FlowTrailing 4 quarters | $-31.1M | $56.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.8M | $63.1M | ||
| Q3 25 | $40.9M | $63.0M | ||
| Q2 25 | $8.9M | $65.0M | ||
| Q1 25 | $-11.3M | $31.2M | ||
| Q4 24 | $50.7M | $45.1M | ||
| Q3 24 | $22.5M | $41.9M | ||
| Q2 24 | $40.4M | $53.5M | ||
| Q1 24 | $15.8M | $30.7M |
| Q4 25 | $-5.4M | $4.0M | ||
| Q3 25 | $25.8M | $23.7M | ||
| Q2 25 | $-11.2M | $26.9M | ||
| Q1 25 | $-40.2M | $1.9M | ||
| Q4 24 | $21.1M | $10.4M | ||
| Q3 24 | $-7.2M | $7.1M | ||
| Q2 24 | $10.7M | $20.6M | ||
| Q1 24 | $291.0K | $-2.4M |
| Q4 25 | -1.2% | 1.0% | ||
| Q3 25 | 6.4% | 6.5% | ||
| Q2 25 | -2.7% | 7.5% | ||
| Q1 25 | -10.5% | 0.6% | ||
| Q4 24 | 4.8% | 3.2% | ||
| Q3 24 | -1.9% | 2.2% | ||
| Q2 24 | 2.6% | 6.5% | ||
| Q1 24 | 0.1% | -0.8% |
| Q4 25 | 4.0% | 14.8% | ||
| Q3 25 | 3.8% | 10.7% | ||
| Q2 25 | 4.8% | 10.7% | ||
| Q1 25 | 7.6% | 9.1% | ||
| Q4 24 | 6.7% | 10.6% | ||
| Q3 24 | 7.8% | 11.0% | ||
| Q2 24 | 7.1% | 10.4% | ||
| Q1 24 | 4.2% | 11.4% |
| Q4 25 | — | 5.34× | ||
| Q3 25 | — | 5.04× | ||
| Q2 25 | — | 3.79× | ||
| Q1 25 | — | 7.36× | ||
| Q4 24 | — | 5.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.54× | ||
| Q1 24 | — | 15.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
SHAK
Segment breakdown not available.
